Compare Salesforce Inc (CRM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs BIO-TECHNE Corp — how do they compare? Salesforce Inc trades at $197.41 (market cap $161.76B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Salesforce Inc is far larger — about 14.4× BIO-TECHNE Corp's market cap, and Salesforce Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| CRM | TECH | |
|---|---|---|
Market Cap | $161.76B | $11.24B |
Sector | Technology | Health |
52-Week High | $266.23 | $72.29 |
52-Week Low | $150.12 | $43.31 |
Enterprise Value | $191.81B | $11.32B |
Dividend Yield | 0.89% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, up 2.45% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $37.90B in 2025, with net income reaching $6.20B and robust profit margins. Analyst consensus is heavily bullish with a $230.61 price target, though recent news highlights volatility in software stocks amid AI-driven market shifts.
Outlook remains positive due to consistent earnings outperformance and AI monetization growth, but risks include sector-wide sell-offs and high RSI levels suggesting overbought conditions. The stock offers value with a P/E of 22.89, supported by solid cash flow and institutional buy ratings.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
